Literature DB >> 1365693

The horror autotoxicus and multiple-organ failure.

A E Baue1.   

Abstract

An injury or operation with tissue injury, ischemia, and sepsis provokes a neuroendocrine, immune, and inflammatory response to promote survival and heal the wound. If the injury is massive or complicated by infection, the inflammatory response may become generalized and excessive, producing organ and tissue damage and multiple-organ failure, a modern "horror autotoxicus." Many inflammatory mediators have been identified. In isolated organs, the use of blocking mediators to prevent combined ischemia-reperfusion injury is feasible. With regional ischemia, activator attenuation may be possible. It is unclear whether blockade or modulation of all or part of an excessive inflammatory response will be possible, helpful, and without hazard in patients with multisystem injuries or sepsis. Feedback loops and control mechanisms of these systems will better define such possibilities. Employment of growth factors and other protective agents to stimulate wound healing, infection control, and host resistance may be more helpful. Ultimately, prevention of multiple-organ failure requires sound surgical judgment, techniques, and organ support.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365693     DOI: 10.1001/archsurg.1992.01420120085016

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  18 in total

1.  Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator.

Authors:  F S Leijten; A W De Weerd; D C Poortvliet; V A De Ridder; C Ulrich; J E Harink-De Weerd
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

Review 2.  The role of the microcirculation in multiple organ dysfunction syndrome (MODS): a review and perspective.

Authors:  C J Kirkpatrick; F Bittinger; C L Klein; S Hauptmann; B Klosterhalfen
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

3.  Intra-abdominal sepsis: an immunocytochemical study of the small intestine mucosa.

Authors:  H B Coutinho; T I Robalinho; V B Coutinho; A M Amorim; A F Furtado; A Ferraz; E Ferraz; F Walker; G King; H F Sewell; D Wakelin
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

Review 4.  Postsurgical complications in older patients. The role of pharmacological intervention.

Authors:  G Zuccalà; A Cocchi; G Gambassi; R Bernabei; P Carbonin
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

Review 5.  Pathophysiology of Pediatric Multiple Organ Dysfunction Syndrome.

Authors:  Joseph A Carcillo; Bradley Podd; Rajesh Aneja; Scott L Weiss; Mark W Hall; Timothy T Cornell; Thomas P Shanley; Lesley A Doughty; Trung C Nguyen
Journal:  Pediatr Crit Care Med       Date:  2017-03       Impact factor: 3.624

6.  Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation?

Authors:  B Leithäuser; F R Matthias; U Nicolai; R Voss
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

7.  Role of endotoxin in the pathogenesis of critical illness polyneuropathy.

Authors:  B Mohammadi; I Schedel; K Graf; A Teiwes; H Hecker; B Haameijer; D Scheinichen; S Piepenbrock; R Dengler; J Bufler
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

Review 8.  Nitric oxide homeostasis as a target for drug additives to cardioplegia.

Authors:  B K Podesser; S Hallström
Journal:  Br J Pharmacol       Date:  2007-05-08       Impact factor: 8.739

9.  Effects of hypothermia and rewarming on the mucosal villus microcirculation and survival after rat intestinal ischemia-reperfusion injury.

Authors:  Neena Kalia; A Graham Pockley; Richard F M Wood; Nicola J Brown
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

10.  Interleukin 10 reduces mortality from severe peritonitis in mice.

Authors:  T Kato; A Murata; H Ishida; H Toda; N Tanaka; H Hayashida; M Monden; N Matsuura
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.